Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362546266> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W4362546266 abstract "<div>Abstract<p>In cancers with tumor-infiltrating lymphocytes (TILs), monoclonal antibodies (mAbs) that block immune checkpoints such as CTLA-4 and PD-1/PD-L1 promote antitumor T-cell immunity. Unfortunately, most cancers fail to respond to single-agent immunotherapies. T regulatory cells, myeloid derived suppressor cells (MDSCs), and extensive stromal networks within the tumor microenvironment (TME) dampen antitumor immune responses by preventing T-cell infiltration and/or activation. Few studies have explored combinations of immune-checkpoint antibodies that target multiple suppressive cell populations within the TME, and fewer have studied the combinations of both agonist and antagonist mAbs on changes within the TME. Here, we test the hypothesis that combining a T-cell–inducing vaccine with both a PD-1 antagonist and CD40 agonist mAbs (triple therapy) will induce T-cell priming and TIL activation in mouse models of nonimmunogenic solid malignancies. In an orthotopic breast cancer model and both subcutaneous and metastatic pancreatic cancer mouse models, only triple therapy was able to eradicate most tumors. The survival benefit was accompanied by significant tumor infiltration of IFNγ-, Granzyme B-, and TNFα-secreting effector T cells. Further characterization of immune populations was carried out by high-dimensional flow-cytometric clustering analysis and visualized by t-distributed stochastic neighbor embedding (t-SNE). Triple therapy also resulted in increased infiltration of dendritic cells, maturation of antigen-presenting cells, and a significant decrease in granulocytic MDSCs. These studies reveal that combination CD40 agonist and PD-1 antagonist mAbs reprogram immune resistant tumors in favor of antitumor immunity.</p></div>" @default.
- W4362546266 created "2023-04-06" @default.
- W4362546266 creator A5001768193 @default.
- W4362546266 creator A5023003658 @default.
- W4362546266 creator A5024136222 @default.
- W4362546266 creator A5034534872 @default.
- W4362546266 creator A5037945090 @default.
- W4362546266 creator A5040720823 @default.
- W4362546266 creator A5050642902 @default.
- W4362546266 creator A5054895913 @default.
- W4362546266 creator A5063962225 @default.
- W4362546266 creator A5065082036 @default.
- W4362546266 creator A5068401950 @default.
- W4362546266 creator A5085518364 @default.
- W4362546266 date "2023-04-03" @default.
- W4362546266 modified "2023-09-29" @default.
- W4362546266 title "Data from A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell–Mediated Anticancer Activity" @default.
- W4362546266 doi "https://doi.org/10.1158/2326-6066.c.6549304.v1" @default.
- W4362546266 hasPublicationYear "2023" @default.
- W4362546266 type Work @default.
- W4362546266 citedByCount "0" @default.
- W4362546266 crossrefType "posted-content" @default.
- W4362546266 hasAuthorship W4362546266A5001768193 @default.
- W4362546266 hasAuthorship W4362546266A5023003658 @default.
- W4362546266 hasAuthorship W4362546266A5024136222 @default.
- W4362546266 hasAuthorship W4362546266A5034534872 @default.
- W4362546266 hasAuthorship W4362546266A5037945090 @default.
- W4362546266 hasAuthorship W4362546266A5040720823 @default.
- W4362546266 hasAuthorship W4362546266A5050642902 @default.
- W4362546266 hasAuthorship W4362546266A5054895913 @default.
- W4362546266 hasAuthorship W4362546266A5063962225 @default.
- W4362546266 hasAuthorship W4362546266A5065082036 @default.
- W4362546266 hasAuthorship W4362546266A5068401950 @default.
- W4362546266 hasAuthorship W4362546266A5085518364 @default.
- W4362546266 hasBestOaLocation W43625462662 @default.
- W4362546266 hasConcept C154317977 @default.
- W4362546266 hasConcept C159654299 @default.
- W4362546266 hasConcept C16930146 @default.
- W4362546266 hasConcept C202751555 @default.
- W4362546266 hasConcept C203014093 @default.
- W4362546266 hasConcept C2776090121 @default.
- W4362546266 hasConcept C2776107976 @default.
- W4362546266 hasConcept C2777701055 @default.
- W4362546266 hasConcept C39347974 @default.
- W4362546266 hasConcept C502942594 @default.
- W4362546266 hasConcept C55493867 @default.
- W4362546266 hasConcept C86803240 @default.
- W4362546266 hasConcept C8891405 @default.
- W4362546266 hasConceptScore W4362546266C154317977 @default.
- W4362546266 hasConceptScore W4362546266C159654299 @default.
- W4362546266 hasConceptScore W4362546266C16930146 @default.
- W4362546266 hasConceptScore W4362546266C202751555 @default.
- W4362546266 hasConceptScore W4362546266C203014093 @default.
- W4362546266 hasConceptScore W4362546266C2776090121 @default.
- W4362546266 hasConceptScore W4362546266C2776107976 @default.
- W4362546266 hasConceptScore W4362546266C2777701055 @default.
- W4362546266 hasConceptScore W4362546266C39347974 @default.
- W4362546266 hasConceptScore W4362546266C502942594 @default.
- W4362546266 hasConceptScore W4362546266C55493867 @default.
- W4362546266 hasConceptScore W4362546266C86803240 @default.
- W4362546266 hasConceptScore W4362546266C8891405 @default.
- W4362546266 hasLocation W43625462661 @default.
- W4362546266 hasLocation W43625462662 @default.
- W4362546266 hasOpenAccess W4362546266 @default.
- W4362546266 hasPrimaryLocation W43625462661 @default.
- W4362546266 hasRelatedWork W2898379310 @default.
- W4362546266 hasRelatedWork W2953174154 @default.
- W4362546266 hasRelatedWork W3015340136 @default.
- W4362546266 hasRelatedWork W3028822667 @default.
- W4362546266 hasRelatedWork W3180719608 @default.
- W4362546266 hasRelatedWork W3193159030 @default.
- W4362546266 hasRelatedWork W4213151053 @default.
- W4362546266 hasRelatedWork W4281389645 @default.
- W4362546266 hasRelatedWork W4286629873 @default.
- W4362546266 hasRelatedWork W4304979265 @default.
- W4362546266 isParatext "false" @default.
- W4362546266 isRetracted "false" @default.
- W4362546266 workType "article" @default.